Selvarajah Abi, Tavenier Anne H, Fabris Enrico, van Leeuwen Maarten A H, Hermanides Renicus S
Department of Cardiology, Isala Hospital, 8025 AB Zwolle, The Netherlands.
Cardiovascular Department, University of Trieste, 34127 Trieste, Italy.
J Clin Med. 2022 Sep 23;11(19):5605. doi: 10.3390/jcm11195605.
The pharmacological treatment strategies for acute coronary syndrome (ACS) in recent years are constantly evolving to develop more potent antithrombotic agents, as reflected by the introduction of more novel P2Y receptor inhibitors and anticoagulants to reduce the ischemic risk among ACS patients. Despite the substantial improvements in the current antithrombotic regimen, a noticeable number of ACS patients continue to experience ischemic events. Providing effective ischemic risk reduction while balancing bleeding risk remains a clinical challenge. This updated review discusses the currently approved and widely used antithrombotic agents and explores newer antithrombotic treatment strategies under development for the initial phase of ACS.
近年来，急性冠状动脉综合征（ACS）的药物治疗策略不断发展，以开发更有效的抗血栓药物，这体现在引入了更多新型P2Y受体抑制剂和抗凝剂，以降低ACS患者的缺血风险。尽管目前的抗血栓治疗方案有了显著改进，但仍有相当数量的ACS患者继续发生缺血事件。在平衡出血风险的同时提供有效的缺血风险降低仍然是一项临床挑战。这篇更新的综述讨论了目前已获批并广泛使用的抗血栓药物，并探讨了正在研发的针对ACS初始阶段的新型抗血栓治疗策略。
